Murat Koçer
Research Subjects
Murat Koçer has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ahsen Oğul
Sports Medicine Section, Eskişehir City Hospital Eskişehir, Türkiye
1 shared publication Banu Ozturk
Department of Medical Oncology Antalya Training and Research Hospital Antalya Türkiye
1 shared publication- Cem Çetin
Sports Medicine Department, Faculty of Medicine, Süleyman Demirel University, Isparta, Türkiye
1 shared publication Derya Kivrak Salim
Department of Medical Oncology Antalya Training and Research Hospital Antalya Türkiye
1 shared publication- Dilek Karadoğan
Department of Chest Diseases, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye
1 shared publication - Esma Arslan
SULEYMAN DEMIREL UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF SPORTS MEDICINE
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 47 (5) , 519-527
Prognostic Factors and Survival Data of Stage I Lung Cancer: A Single-Center Experience
Objective: Even in stage I lung cancer, the heightened risk of recurrence may lead to diminished survival rates. Only a few reports on prognostic factors have been published for stage I disease using the most recent staging system. This study was designed to identify predictive factors of recurrence and survival in early-stage lung cancer (LC) staged according to the eighth edition of the Tumor, Node, Metastasis (TNM) classification. Materials and Methods: The clinicopathological characteristics, treatment, and follow-up data of 100 stage I patients monitored between 2013 and 2023 were retrospectively reviewed. The association between clinicopathological factors and survival was analyzed to identify prognostic factors. Results: The median age was 61 years (range, 35–76). All patients had a histologic diagnosis of non-small cell lung cancer, with 62% being adenocarcinoma. During a median follow-up of 40.3 months (range, 1–183.5), 20 patients experienced recurrence and 16 died. The two-year and five-year disease-free survival (DFS) rates were 81% and 73%, respectively, while overall survival (OS) rates for the same periods were 86% and 77%. Multivariate analysis revealed that a smoking history greater than 40 pack-years (p=0.021) and perineural invasion (PNI) (p=0.049) were predictors of recurrence, while the presence of lymphovascular invasion (LVI) was significantly associated with OS (p=0.019). Conclusion: Smoking significantly increases the risk of LC development and recurrence, making it crucial to promote smoking cessation. Patients with positive LVI or PNI in early-stage LC should be monitored more closely, although further research is warranted.
- 1 January 2025
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 47 (5) , 519-527
Open AccessPrognostic Factors and Survival Data of Stage I Lung Cancer: A Single-Center Experience
Objective: Even in stage I lung cancer, the heightened risk of recurrence may lead to diminished survival rates. Only a few reports on prognostic factors have been published for stage I disease using the most recent staging system. This study was designed to identify predictive factors of recurrence and survival in early-stage lung cancer (LC) staged according to the eighth edition of the Tumor, Node, Metastasis (TNM) classification. Materials and Methods: The clinicopathological characteristics, treatment, and follow-up data of 100 stage I patients monitored between 2013 and 2023 were retrospectively reviewed. The association between clinicopathological factors and survival was analyzed to identify prognostic factors. Results: The median age was 61 years (range, 35–76). All patients had a histologic diagnosis of non-small cell lung cancer, with 62% being adenocarcinoma. During a median follow-up of 40.3 months (range, 1–183.5), 20 patients experienced recurrence and 16 died. The two-year and five-year disease-free survival (DFS) rates were 81% and 73%, respectively, while overall survival (OS) rates for the same periods were 86% and 77%. Multivariate analysis revealed that a smoking history greater than 40 pack-years (p=0.021) and perineural invasion (PNI) (p=0.049) were predictors of recurrence, while the presence of lymphovascular invasion (LVI) was significantly associated with OS (p=0.019). Conclusion: Smoking significantly increases the risk of LC development and recurrence, making it crucial to promote smoking cessation. Patients with positive LVI or PNI in early-stage LC should be monitored more closely, although further research is warranted.
- Open Access
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1838-1850
Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer
Background/aim: This study aimed to investigate the effect of clinical and pathological indicators at the tone of the diagnosis on overall survival in patients recently diagnosed with non-small cell lung cancer. Materials and methods: The study population consisted of patients who were diagnosed at the Faculty of Medicine at Isparta Silleyman Demirel University Hospital between January 1, 2010 and December 31, 2017 and presented to the medical oncology outpatient clinic. Results: A total of 518 patients were evaluated, including 260 patients with squamous cell carcinoma, 207 patients with adenocarcinoma, 50 patients with non-small cell lung cancer-not otherwise specified, and 1 patient with large cell carcinoma. The average life expectancy was found to be 11.50 +/- 1.40 months in patients with squamous cell carcinoma, 12.60 +/- 1.59 months in patients with adenocarcinoma, and 8.70 +/- 1.87 months in the other patients. The estimated 5-year relative survival rate for non-small cell lung cancer was 8% (7% for men and 18% for women). In the multivariate analysis, sex being male (HR, 2.41; P < 0.001), a performance status >2 (HR, 1.70; P < 0.001), the stage of cancer (HR, 1.37; P = 0.045), the presence of bone or liver metastasis (HR, 1.44, P = 0.009, HR, 1.57; P = 0.016, respectively), and the patient not having received radiotherapy (HR, 3.25; P < 0.001) or chemotherapy (HR, 1.85; P = 0.001) were defined as statistically significant predictive factors that reduced the overall survival. Conclusions: In this study, sex, stage, performance status, the presence of liver or bone metastases, and treatment had an effect on overall survival.
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1838-1850
Open AccessSurvival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer
Background/aim: This study aimed to investigate the effect of clinical and pathological indicators at the tone of the diagnosis on overall survival in patients recently diagnosed with non-small cell lung cancer. Materials and methods: The study population consisted of patients who were diagnosed at the Faculty of Medicine at Isparta Silleyman Demirel University Hospital between January 1, 2010 and December 31, 2017 and presented to the medical oncology outpatient clinic. Results: A total of 518 patients were evaluated, including 260 patients with squamous cell carcinoma, 207 patients with adenocarcinoma, 50 patients with non-small cell lung cancer-not otherwise specified, and 1 patient with large cell carcinoma. The average life expectancy was found to be 11.50 +/- 1.40 months in patients with squamous cell carcinoma, 12.60 +/- 1.59 months in patients with adenocarcinoma, and 8.70 +/- 1.87 months in the other patients. The estimated 5-year relative survival rate for non-small cell lung cancer was 8% (7% for men and 18% for women). In the multivariate analysis, sex being male (HR, 2.41; P < 0.001), a performance status >2 (HR, 1.70; P < 0.001), the stage of cancer (HR, 1.37; P = 0.045), the presence of bone or liver metastasis (HR, 1.44, P = 0.009, HR, 1.57; P = 0.016, respectively), and the patient not having received radiotherapy (HR, 3.25; P < 0.001) or chemotherapy (HR, 1.85; P = 0.001) were defined as statistically significant predictive factors that reduced the overall survival. Conclusions: In this study, sex, stage, performance status, the presence of liver or bone metastases, and treatment had an effect on overall survival.